"Hope and Uncertainty: The Final HIV Vaccine Trial of the Decade"

The PrEPVacc trial, currently underway in Africa, is testing two HIV vaccines alongside pre-exposure prophylaxis (PrEP) to determine vaccine efficacy and prevent the spread of HIV. The trial marks a crucial stage in HIV vaccine development, with hopes that it will succeed where previous trials have failed. If successful, it could lead to a new phase of vaccine development; if not, it may result in immunologists giving up on this generation of vaccines. The trial, led by African researchers and coordinated in Africa, aims to achieve an efficacy of at least 70% for either of the two vaccines being tested. The results are expected to be released in the fourth quarter of 2024.